Challenges To The Orthopedic Biomaterials Market In 2019

• Although the market continues to grow year over year, average selling prices (ASPs) are declining as a result of these pressures. Our research shows that these ASPs are declining at a rate of nearly 5 percent annually across particular segments of this market.
• Orthopedic Biomaterial Products Face Reimbursement Challenges.
• Manufacturers Pushed To Lower Prices On Premium Products.
• Increased Product Diversification.

Conclusion

Growth in the U.S. orthopedic biomaterials market will continue, driven by increasing demand for orthopedic procedures, as well as the emergence of new products. The market will become more competitive, likely leading to significant pricing changes – mostly reductions. The lowered prices are expected to be offset by the massive growth potential in unit sales.

However, competition is not the only factor driving prices down. Many orthopedic biomaterial products are scrutinized by health insurance providers and are not eligible for reimbursement. Without reimbursement, treatments using these products become far too expensive for many patients, leading to pressure on manufacturers to lower prices even further.